November 18-20, 2026 | Barcelona
EORTC-NCI-AACR Symposium 2026
The EORTC-NCI-AACR Symposium covers molecular targets and cancer therapeutics, with a focus on translational oncology and early clinical development.
Peregrion attends to meet sponsors moving oncology assets into first-in-human studies, particularly those with bioavailability, metabolite characterisation, or radiolabel synthesis questions.
Activities
1:1 sponsor meetings around the symposium.
Attending from Peregrion
- Steven Erpelinck (Chief Commercial Officer)
- Suzanne van Gerwen (VP Business Development)
Topics for discussion
- Microtracer human ADME for oncology assets in early clinical development
- MIST package generation and metabolite data from Phase 1
- Mass balance and bioavailability work for oncology compounds
- AMS for compounds with complex synthesis or limited material availability
- Oncology program-specific discussions
Book a meeting with our team: info@peregrion.com.
